Extracellular vesicles in targeted drug delivery: from biological functions to surface engineering.

IF 13 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY
Giulia Duca, Vincenza Tinnirello, Nima Rabienezhad Ganji, Riccardo Alessandro, Stefania Raimondo
{"title":"Extracellular vesicles in targeted drug delivery: from biological functions to surface engineering.","authors":"Giulia Duca, Vincenza Tinnirello, Nima Rabienezhad Ganji, Riccardo Alessandro, Stefania Raimondo","doi":"10.1186/s43556-026-00578-2","DOIUrl":null,"url":null,"abstract":"<p><p>Achieving precise and efficient targeting represents a major challenge in drug delivery to overcome the limitations of conventional therapies. Surface functionalization of extracellular vesicles (EVs)-nanosized membranous particles released by all cell types- has emerged as a promising strategy to enhance targeted drug delivery. EVs are naturally involved in intercellular communication by transferring bioactive molecules from donor to recipient cells, and their biologically active interface confers inherent targeting properties and a favorable safety profile, making them attractive vehicles compared to synthetic nanoparticles. However, the naїve use of EVs is often limited by nonspecific biodistribution and off-target accumulation, reducing their therapeutic efficacy. To overcome these limitations, increasing efforts have focused on engineering EVs through cargo loading and surface functionalization strategies, enabling enhanced targeting and improved delivery of therapeutic molecules. In this review, we first describe the biological features of EVs, including their biogenesis, heterogeneity, and molecular composition, which underlie their potential as drug delivery systems. We then discuss the main determinants of EV-mediated drug delivery and present current engineering strategies, including cargo loading and surface functionalization approaches, highlighting their advantages and limitations. Finally, we summarize the application of engineered EVs in the treatment of several pathological conditions, including cardiovascular, neurological, autoimmune, and cancer diseases, and discuss the major challenges in clinical translation and future perspectives for EV-based targeted therapies.</p>","PeriodicalId":74218,"journal":{"name":"Molecular biomedicine","volume":"7 1","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13582709/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular biomedicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s43556-026-00578-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Achieving precise and efficient targeting represents a major challenge in drug delivery to overcome the limitations of conventional therapies. Surface functionalization of extracellular vesicles (EVs)-nanosized membranous particles released by all cell types- has emerged as a promising strategy to enhance targeted drug delivery. EVs are naturally involved in intercellular communication by transferring bioactive molecules from donor to recipient cells, and their biologically active interface confers inherent targeting properties and a favorable safety profile, making them attractive vehicles compared to synthetic nanoparticles. However, the naїve use of EVs is often limited by nonspecific biodistribution and off-target accumulation, reducing their therapeutic efficacy. To overcome these limitations, increasing efforts have focused on engineering EVs through cargo loading and surface functionalization strategies, enabling enhanced targeting and improved delivery of therapeutic molecules. In this review, we first describe the biological features of EVs, including their biogenesis, heterogeneity, and molecular composition, which underlie their potential as drug delivery systems. We then discuss the main determinants of EV-mediated drug delivery and present current engineering strategies, including cargo loading and surface functionalization approaches, highlighting their advantages and limitations. Finally, we summarize the application of engineered EVs in the treatment of several pathological conditions, including cardiovascular, neurological, autoimmune, and cancer diseases, and discuss the major challenges in clinical translation and future perspectives for EV-based targeted therapies.

靶向药物递送中的细胞外囊泡:从生物学功能到表面工程。
实现精确和有效的靶向是克服传统疗法局限性的药物递送的主要挑战。细胞外囊泡(EVs)是由所有细胞类型释放的纳米级膜状颗粒,其表面功能化已成为增强靶向药物递送的一种有前途的策略。通过将生物活性分子从供体细胞转移到受体细胞,电动汽车自然参与细胞间通讯,其生物活性界面赋予其固有的靶向特性和良好的安全性,使其与合成纳米颗粒相比更具吸引力。然而,naїve ev的使用往往受到非特异性生物分布和脱靶积累的限制,从而降低了其治疗效果。为了克服这些限制,越来越多的人致力于通过货物装载和表面功能化策略来设计电动汽车,从而增强靶向性和改善治疗分子的递送。在这篇综述中,我们首先描述了电动汽车的生物学特性,包括它们的生物发生、异质性和分子组成,这是它们作为药物传递系统潜力的基础。然后,我们讨论了ev介导的药物递送的主要决定因素,并介绍了当前的工程策略,包括货物装载和表面功能化方法,强调了它们的优点和局限性。最后,我们总结了工程化ev在治疗多种病理疾病(包括心血管、神经、自身免疫和癌症疾病)中的应用,并讨论了临床转化中的主要挑战和基于ev的靶向治疗的未来前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.30
自引率
0.00%
发文量
0
审稿时长
10 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书